 Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma HCC at high risk of recurrence following surgery met primary endpoint of recurrence-free survival New adjuvant treatments are urgently needed as an estimated 70-80 of people with early-stage HCC experience disease recurrence following surgery1 Data will be discussed with health... The post Ad hoc announcement pursuant to Art. 53 LR Roches Tecentriq plus Avastin is the f... 